64% of obese teen GLP1Ra prescriptions denied by insurance, per ENDO 2024 study.
Insurance often denies GLP-1 medications for teens with obesity and type 2 diabetes, according to a study at ENDO 2024. GLP-1 receptor agonists (GLP1Ra) are often denied despite FDA approval, especially if children don't have type 2 diabetes. In a study of 599 children, aged 15 on average, insurance denied GLP1Ra prescriptions in 64% of patients with obesity and 32% of those with type 2 diabetes, with 58% on public insurance.
June 01, 2024
3 Articles